Proliferative Vitreoretinopathy clinical trials at UC Health

• The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

  open to eligible people ages 18 years and up

  The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.

  at UCLA

Last updated: July 2, 2020